Literature DB >> 21553745

Prevention of VTE Following total hip and knee arthroplasty in Hemophilia patients.

Matthew I Stein1, Justin Park, Stephen Raterman.   

Abstract

The often debilitating condition of hemophilic arthropathy is treated with elective total joint arthroplasty. Little has been published addressing the role of thromboembolic prophylaxis in the hemophilic patient population following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Although the American College of Chest Physicians and the American Academy of Orthopaedic Surgeons have set guidelines for thromboembolic prophylaxis in the general population, no such standard of care is in place for hemophilic patients. While the risk of thrombosis in hemophilic patients following THA and TKA is thought to be lower, cases have been reported of pulmonary embolism and deep vein thrombosis (DVT) in hemophilic patients. Copyright 2011, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553745     DOI: 10.3928/01477447-20110317-21

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  4 in total

1.  Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up.

Authors:  Guo-Liang Wu; Ji-Liang Zhai; Bin Feng; Yan-Yan Bian; Chi Xu; Xi-Sheng Weng
Journal:  Orthop Surg       Date:  2017-11       Impact factor: 2.071

2.  Total Hip Arthroplasty in Patients With Classic Hemophilia: A Matched Comparison of 90-Day Outcomes and 5-Year Implant Survival.

Authors:  Stephen M Gillinov; Patrick J Burroughs; Harold G Moore; Lee E Rubin; David B Frumberg; Jonathan N Grauer
Journal:  J Arthroplasty       Date:  2022-03-04       Impact factor: 4.435

Review 3.  Venous Thromboembolism in Children with Cancer and Blood Disorders.

Authors:  Richard H Ko; Courtney D Thornburg
Journal:  Front Pediatr       Date:  2017-02-06       Impact factor: 3.418

4.  Simultaneous bilateral total knee arthroplasty in patients with end-stage hemophilic arthropathy: a mean follow-up of 6 years.

Authors:  Chao Jiang; Yan Zhao; Bin Feng; Jiliang Zhai; Yanyan Bian; Guixing Qiu; Xisheng Weng
Journal:  Sci Rep       Date:  2018-01-25       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.